Spherix Global Insights Launches Market Dynamix™: PD-1 Inhibition in Solid Tumors, Delivering a Comprehensive Assessment of Biosimilar and Subcutaneous PD-1 Market Dynamics Across Key Oncology ...

A subgroup analysis of patients with moderately to severely active Crohn’s disease showed greater clinical and endoscopic ...

Discover Biogen's Q3 2025 earnings: 67% launch product growth, strategic pipeline expansion, and updated guidance amid evolving market dynamics.

In head-to-head non-human primate (NHP) studies, average observed half-life of ASC36 was approximately 15 days, 3-fold longer than petrelintide, which supports once-monthly subcutaneous (SQ) dosing in ...

Patient education conversations emphasize 3 core elements: equivalent efficacy supported by rigorous pharmacokinetic and clinical trial data, comparable safety profiles with identical immune-related ...

Over the past decade, subcutaneous formulations of anticancer drugs—originally administered intravenously—have been ...

A phase 1/2 study showed durable remission, manageable safety in pts with R/R follicular lymphoma who received fixed-duration mosunetuzumab.in.

Operationalizing Subcutaneous Checkpoint Inhibitors in Practice. Implementing subcutaneous checkpoint inhibitors requires ...

Balazs Halmos, MD, discussed the potential impact of subcutaneous amivantamab for patients with EGFR -mutated NSCLC. Halmos oversees the thoracic clinical trials program of novel clinical studies at ...

Saphnelo can now be administered subcutaneously rather than intravenously following the European regulator’s recommendation.

In September 2025, Merck received FDA approval for KEYTRUDA QLEX, a subcutaneous version of its flagship cancer therapy, allowing for one- to two-minute administration across 38 solid tumor ...

Lunsumio provides high and long-lasting response rates, with approximately two-thirds of patients with a complete response in remission after four years 1 Subcutaneous Lunsumio has potential to ...